Development Of Biopharmaceuticals And Vaccines In The Region Will Be Better Between Panama And Brazil -
The agreement, contained in the presidential declaration, highlights the importance of boosting regional capacity for the production of vaccines and biopharmaceuticals, with the goal of addressing the public health needs of Panama, Brazil, and, in particular, Central America and the Caribbean. This commitment aligns with the efforts led by Senacyt to create the Regional Center for Innovation in Vaccines and Biopharmaceuticals (CRIVB), a strategic initiative that seeks to position Panama as a regional benchmark in biopharmaceutical research, development, and production. Fiocruz, a leading institution in public health, biomedical research, and vaccine production in Brazil, will be a key partner in this joint effort.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- United States Lubricants Market Growth Opportunities & Share Dynamics 20252033
- UK Digital Health Market To Reach USD 37.6 Billion By 2033
- Immigration Consultancy Business Plan 2025: What You Need To Get Started
- United States Animal Health Market Size, Industry Trends, Share, Growth And Report 2025-2033
- Latin America Mobile Payment Market To Hit USD 1,688.0 Billion By 2033
- United States Jewelry Market Forecast On Growth & Demand Drivers 20252033
Comments
No comment